ASIS for Enbrel in Plaque Psoriasis

NCT02112097 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis.

Interventions

DRUG: Gadolinium
DRUG: Gadolinium
DRUG: Gadolinium
DRUG: Efficacy of Enbrel subcutaneously at Week 12
DRUG: Efficacy of Enbrel subcutaneously at Week 24
DRUG: Efficacy of Enbrel subcutaneously at Week 36
DRUG: Efficacy of Enbrel subdermally at Week 12
DRUG: Efficacy of Enbrel subdermally at Week 24
DRUG: Efficacy of Enbrel subdermally at Week 36
DRUG: PASI 75 n(%) subcutaneously at Week 12
DRUG: PASI 75 n(%) subcutaneously at Week 24
DRUG: PASI 75 n(%) subcutaneously at Week 36
DRUG: PASI 75 n(%) subdermally at Week 12
DRUG: PASI 75 n(%) subdermally at Week 24
DRUG: PASI 75 n(%) subdermally at Week 36
DRUG: Adverse Reactions of Enbrel subcutaneously
DRUG: Adverse Reactions of Enbrel subdermally at Week 36
DRUG: Gadolinium
DRUG: Gadolinium
DRUG: Gadolinium

Sponsor

ASIS Corporation